Yifan Yang

Yifan Yang

Auto-generated profile, based on publicly available information

Yifan Yang

School of Management, Xi’an Jiao Tong University, Xi’an, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 November 2023 in International Journal of Forecasting
Verified
Journal Article
Closed access
YYYifan Yang
Yifan Yang
JGJu’e Guo
Ju’e Guo
YLYi Li
Yi Li
Jiandong ZhouJiandong Zhou
Jiandong Zhou

22 May 2025 in Cancer Prevention Research
Verified
Journal Article
Open access
LLLifang Li
Lifang Li
HCHou In Chou
Hou In Chou
KMKar Kei Mak
Kar Kei Mak
YYYifan Yang
Yifan Yang
CCCheuk To Chung
Cheuk To Chung
Jiandong ZhouJiandong Zhou
Jiandong Zhou
Nasopharyngeal carcinoma (NPC) remains a major endemic disease in parts of Asia especially Southern China and Southest Asia, the risk factors of which are distinct from other head and neck cancers. Antidiabetic drugs have been proposed to reduce the risk of NPC. The associations between sodium–glucose cotransporter 2 inhibitors (SGLT2I) versus dipeptidyl peptidase-4 inhibitors (DPP4I) and the risks of NPC and head and neck cancer among patients with type 2 diabetes mellitus (T2DM) remain unknown. This was a population-based cohort study including patients with T2DM treated with either an SGLT2I or a DPP4I between January 1, 2015, and December 31, 2019, in Hong Kong. Propensity score matching (1:1 ratio) was performed using the nearest neighbor search. Multivariable Cox regression was applied to identify significant predictors. The primary outcome was new-onset NPC and other head and neck cancers. We found that patients with T2DM were treated with either an SGLT2I or a DPP4I between January 1, 2015, and December 31, 2019, in Hong Kong. This cohort included 75,884 patients with T2DM, among whom 28,778 patients were on an SGLT2I and 47,106 patients were on a DPP4I. After matching (57,556 patients), 106 patients developed NPC and 50 patients developed head and neck cancer. Compared with DPP4Is, SGLT2Is were associated with lower risks of NPC (HR, 0.41; 95% confidence interval, 0.21–0.81) but not of head and neck cancer (HR, 1.00; 95% confidence interval, 0.26–3.92) after adjustments. The association remained consistent in different risk models, matching approaches, and sensitivity analysis. In conclusion, this study provided real-world evidence that SGLT2Is were associated with lower risks of NPC but not of head and neck cancer when compared with DPP4Is among patients with T2DM, whereas their biological effects need future confirmation. Prevention Relevance: This study provided real-world evidence that SGLT2Is were associated with lower risks of NPC but not of head and neck cancer when compared with DPP4Is among patients with T2DM. SGLT2Is should be considered before DPP4Is about the risks of NPC in regions with high prevalence of NPC.

3 November 2023
Verified
Conference Paper
Closed access
SDSong Deng
Song Deng
ZTZhukui Tan
Zhukui Tan
BLBin Liu
Bin Liu
YYYifan Yang
Yifan Yang
ZCZhiwei Chen
Zhiwei Chen
As the reform of the electricity market deepens, the integration of electric vehicles (EV) into the power grid can serve as a form of distributed energy storage, providing regulatory capabilities similar to battery energy storage. Exploring the potential of Electric Vehicle Aggregations (EVA) in participating in the ancillary services market can lead to a mutually beneficial outcome, achieving user benefits and ensuring the economic operation of the power grid. Building upon this, this paper proposes a framework and transaction process for simultaneous participation of multiple EVAs in the electricity and frequency regulation ancillary services markets. This framework is designed to meet user charging needs while establishing bid optimization strategies for the day-ahead market which take into account demand responsiveness and opportunity costs. This approach not only enhances user benefits but also improves the economic viability of EVA participation in ancillary services market regulation.

1 October 2025
Verified
Other
Open access
LLLifang Li
Lifang Li
HCHou In Chou
Hou In Chou
KMKar Kei Mak
Kar Kei Mak
YYYifan Yang
Yifan Yang
CCCheuk To Chung
Cheuk To Chung
Jiandong ZhouJiandong Zhou
Jiandong Zhou
Supplementary Figure S2: Marginal effects of the demographics, number of anti-diabetic drugs, renal function, and time-weighted mean of HbA1C with 95% CIs on new onset NPC and H&N cancer stratified by drug use in the matched cohort.

1 October 2025
Verified
Other
Open access
LLLifang Li
Lifang Li
HCHou In Chou
Hou In Chou
KMKar Kei Mak
Kar Kei Mak
YYYifan Yang
Yifan Yang
CCCheuk To Chung
Cheuk To Chung
Jiandong ZhouJiandong Zhou
Jiandong Zhou
Supplementary Table S2: Sensitivity analyses for exposure effects of SGLT2I v.s. DPP4I on new onset nasopharyngeal cancer, new onset salivary gland and other head/neck cancer, cancer related mortality, all-cause mortality in the matched cohort using different models.

1 October 2025
Verified
Other
Open access
LLLifang Li
Lifang Li
HCHou In Chou
Hou In Chou
KMKar Kei Mak
Kar Kei Mak
YYYifan Yang
Yifan Yang
CCCheuk To Chung
Cheuk To Chung
Jiandong ZhouJiandong Zhou
Jiandong Zhou
Nasopharyngeal carcinoma (NPC) remains a major endemic disease in parts of Asia especially Southern China and Southest Asia, the risk factors of which are distinct from other head and neck cancers. Antidiabetic drugs have been proposed to reduce the risk of NPC. The associations between sodium–glucose cotransporter 2 inhibitors (SGLT2I) versus dipeptidyl peptidase-4 inhibitors (DPP4I) and the risks of NPC and head and neck cancer among patients with type 2 diabetes mellitus (T2DM) remain unknown. This was a population-based cohort study including patients with T2DM treated with either an SGLT2I or a DPP4I between January 1, 2015, and December 31, 2019, in Hong Kong. Propensity score matching (1:1 ratio) was performed using the nearest neighbor search. Multivariable Cox regression was applied to identify significant predictors. The primary outcome was new-onset NPC and other head and neck cancers. We found that patients with T2DM were treated with either an SGLT2I or a DPP4I between January 1, 2015, and December 31, 2019, in Hong Kong. This cohort included 75,884 patients with T2DM, among whom 28,778 patients were on an SGLT2I and 47,106 patients were on a DPP4I. After matching (57,556 patients), 106 patients developed NPC and 50 patients developed head and neck cancer. Compared with DPP4Is, SGLT2Is were associated with lower risks of NPC (HR, 0.41; 95% confidence interval, 0.21–0.81) but not of head and neck cancer (HR, 1.00; 95% confidence interval, 0.26–3.92) after adjustments. The association remained consistent in different risk models, matching approaches, and sensitivity analysis. In conclusion, this study provided real-world evidence that SGLT2Is were associated with lower risks of NPC but not of head and neck cancer when compared with DPP4Is among patients with T2DM, whereas their biological effects need future confirmation.Prevention Relevance:This study provided real-world evidence that SGLT2Is were associated with lower risks of NPC but not of head and neck cancer when compared with DPP4Is among patients with T2DM. SGLT2Is should be considered before DPP4Is about the risks of NPC in regions with high prevalence of NPC.